

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

**Apremilast for treating moderate to severe plaque
psoriasis (rapid review of TA368)**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Appraisal Consultation Document

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how? |
|---|

No equality issues were identified during the scoping process.
--

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these? |
|--|

No

- | |
|--|
| 3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these? |
|--|

No.

- | |
|--|
| 4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group? |
|--|

No.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

The recommendations apply to people with severe psoriasis, and the Dermatology Life Quality Index (DLQI) is one of the tools used to define disease severity. No equality issues were raised around this, but it was noted that a previous appraisal of [secukinumab \(TA350\)](#) identified that when using the DLQI, healthcare professionals should take into account any physical, sensory or learning disabilities, or communication difficulties, that could affect the responses to the DLQI and make any adjustments they consider appropriate. This consideration is also relevant to this appraisal.

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Section 1.3 in the ACD states that 'When using the DLQI, healthcare professionals should take into account any physical, sensory or learning disabilities, or communication difficulties, that could affect the responses to the DLQI and make any adjustments they consider appropriate.'

7. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Section 1.3 and summary table in the FAD.

Approved by Associate Director (name): Melinda Goodall

Date: 26/07/2016

Technology appraisals: Guidance development

Equality impact assessment for the rapid review of apremilast for treating moderate to severe plaque psoriasis (review of TA368)

Issue date: December 2016

Final appraisal determination

(when an ACD issued)

8. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No potential equality issues have been raised during consultation.

9. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

The recommendations changed after consultation, but this change does not make it more difficult in practice for a specific group to access the technology compared with other groups.

10. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

11. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

12. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?
Not applicable.

Approved by Centre or Programme Director (name): Meindert Boysen

Date: 19/12/2016